{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Combination+Agent&page=3",
    "query": {
      "intervention": "Combination Agent",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 5568,
    "total_pages": 557,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Combination+Agent&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Combination+Agent&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-15T09:12:48.151Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04698564",
      "title": "Utility of Hyperpolarized 13C-pyruvate Metabolic Magnetic Resonance Imaging",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Hyperpolarized 13C-Pyruvate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Maryland, Baltimore",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "80 Years",
        "sex": "MALE",
        "summary": "40 Years to 80 Years · Male only"
      },
      "enrollment_count": 4,
      "start_date": "2020-12-01",
      "completion_date": "2025-12-05",
      "has_results": true,
      "last_update_posted_date": "2026-07-15",
      "last_synced_at": "2026-11-15T09:12:48.151Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04698564"
    },
    {
      "nct_id": "NCT06877533",
      "title": "A First-in-Human Open-label, Phase I/Ib Dose Escalation and Expansion Cohort Study of EOS006215 as Monotherapy and in Combination With Pembrolizumab or Other Anticancer Treatments in Participants With Advanced Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Selected Advanced Solid Tumors"
      ],
      "interventions": [
        {
          "name": "EOS006215",
          "type": "DRUG"
        },
        {
          "name": "Anticancer agent",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "iTeos Belgium SA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3,
      "start_date": "2025-04-07",
      "completion_date": "2025-07-10",
      "has_results": false,
      "last_update_posted_date": "2025-08-12",
      "last_synced_at": "2026-11-15T09:12:48.151Z",
      "location_count": 2,
      "location_summary": "Denver, Colorado • Sarasota, Florida",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06877533"
    },
    {
      "nct_id": "NCT06031441",
      "title": "A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Locally Advanced Solid Tumors",
        "Recurrent Solid Tumors",
        "Metastatic Solid Tumors"
      ],
      "interventions": [
        {
          "name": "RO7566802",
          "type": "DRUG"
        },
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genentech, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 65,
      "start_date": "2023-11-27",
      "completion_date": "2028-03-01",
      "has_results": false,
      "last_update_posted_date": "2026-11-04",
      "last_synced_at": "2026-11-15T09:12:48.151Z",
      "location_count": 6,
      "location_summary": "Birmingham, Alabama • New Haven, Connecticut • New York, New York + 3 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Harrisburg",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06031441"
    },
    {
      "nct_id": "NCT01903005",
      "title": "Multi-Center, Open-Label, 24-Week Study of OX219 Safety and Efficacy for Maintenance Treatment of Opioid Dependence",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Opioid Dependence, on Agonist Therapy"
      ],
      "interventions": [
        {
          "name": "Higher bioavailability BNX sublingual tablets",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Orexo AB",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 668,
      "start_date": "2013-07",
      "completion_date": "2014-09",
      "has_results": true,
      "last_update_posted_date": "2015-10-28",
      "last_synced_at": "2026-11-15T09:12:48.151Z",
      "location_count": 28,
      "location_summary": "Jefferson County, Alabama • Marion County, Alabama • Winston County, Alabama + 25 more",
      "locations": [
        {
          "city": "Jefferson County",
          "state": "Alabama"
        },
        {
          "city": "Marion County",
          "state": "Alabama"
        },
        {
          "city": "Winston County",
          "state": "Alabama"
        },
        {
          "city": "Maricopa County",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles County",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01903005"
    },
    {
      "nct_id": "NCT00409851",
      "title": "One Year Study to Evaluate the Safety of the Combination of Valsartan and Amlodipine in Patients With Hypertension",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hypertension"
      ],
      "interventions": [
        {
          "name": "valsartan+amlodipine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1293,
      "start_date": "2003-04",
      "completion_date": "2005-03",
      "has_results": false,
      "last_update_posted_date": "2011-11-08",
      "last_synced_at": "2026-11-15T09:12:48.151Z",
      "location_count": 1,
      "location_summary": "East Hanover, New Jersey",
      "locations": [
        {
          "city": "East Hanover",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00409851"
    },
    {
      "nct_id": "NCT00771810",
      "title": "Study of Drug to Reduce Thrombocytopenia in Patients Receiving Chemo for Ovarian, Fallopian Tube or Peritoneal Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Thrombocytopenia",
        "Neutropenia",
        "Lymphopenia",
        "Anemia"
      ],
      "interventions": [
        {
          "name": "TXA127",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tarix Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 34,
      "start_date": "2008-10",
      "completion_date": "2011-12",
      "has_results": true,
      "last_update_posted_date": "2017-11-13",
      "last_synced_at": "2026-11-15T09:12:48.151Z",
      "location_count": 6,
      "location_summary": "Mobile, Alabama • Los Angeles, California • Orange, California + 3 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Wichita",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00771810"
    },
    {
      "nct_id": "NCT06471673",
      "title": "A Study of BRIA-OTS Cellular Immunotherapy in Metastatic Recurrent Breast Cancer",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer",
        "Breast Tumor",
        "Cancer of Breast",
        "Cancer of the Breast",
        "Malignant Tumor of Breast",
        "Tumors, Breast"
      ],
      "interventions": [
        {
          "name": "BC1 cell line",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Bria-OTS regimen and CPI (tislelizumab)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Bria-OTS regimen and CPI (tislelizumab) expansion cohort",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "BriaCell Therapeutics Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2024-05-29",
      "completion_date": "2025-10-30",
      "has_results": false,
      "last_update_posted_date": "2024-08-26",
      "last_synced_at": "2026-11-15T09:12:48.151Z",
      "location_count": 1,
      "location_summary": "Santa Monica, California",
      "locations": [
        {
          "city": "Santa Monica",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06471673"
    },
    {
      "nct_id": "NCT07123454",
      "title": "A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "B-cell Non-Hodgkin Lymphoma"
      ],
      "interventions": [
        {
          "name": "AZD4512",
          "type": "DRUG"
        },
        {
          "name": "Surovatamig",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 164,
      "start_date": "2025-09-24",
      "completion_date": "2029-02-15",
      "has_results": false,
      "last_update_posted_date": "2026-11-02",
      "last_synced_at": "2026-11-15T09:12:48.151Z",
      "location_count": 8,
      "location_summary": "Irvine, California • Jacksonville, Florida • Rochester, Minnesota + 4 more",
      "locations": [
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07123454"
    },
    {
      "nct_id": "NCT00002154",
      "title": "A Study of Thioctic Acid and Deprenyl in HIV-Infected Patients With Dementia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cognitive Disorders",
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Thioctic acid",
          "type": "DRUG"
        },
        {
          "name": "Selegiline hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The Dana Foundation",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 32,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2005-06-24",
      "last_synced_at": "2026-11-15T09:12:48.151Z",
      "location_count": 3,
      "location_summary": "Baltimore, Maryland • New York, New York • Rochester, New York",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00002154"
    },
    {
      "nct_id": "NCT02658396",
      "title": "GO-203-2C + Bortezomib For Relapsed Or Refractory MM",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Multiple Myeloma",
        "Multiple Myeloma in Relapse",
        "Refractory Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "GO-203-2C",
          "type": "DRUG"
        },
        {
          "name": "Bortezomib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": null,
      "completion_date": "2022-01",
      "has_results": false,
      "last_update_posted_date": "2017-07-05",
      "last_synced_at": "2026-11-15T09:12:48.151Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02658396"
    }
  ]
}